{"name":"Bay Area Retina Associates","slug":"bay-area-retina-associates","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ozurdex","genericName":"Ozurdex","slug":"ozurdex","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Ozurdex","genericName":"Ozurdex","slug":"ozurdex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOa1NuMUpEUjJxY3NDOU8xVzkzejBlWGpCbm1aeWFidzRMeWpfMTJLc2NSeDhtczBhME9oc3M5WUJ1ZU96YUVlLXIzM19WVllEWTloSWR2d2FEelA3aUJ4Sy1CNWJQc1R5X051RDhoSkpwWjF2MTl3Y1R1U3I3QXo0NjAzTlluNzVIeVg2R0dDOEszU29tWV9Jb3NzaUlQQ3JmbllHdWpGb28taUctUmFKZmNXZVVqdm95d3lYU25fYTZjajJrU05QaEgwUnZ0R3hRTnJzWEVB?oc=5","date":"2025-10-19","type":"trial","source":"Modern Retina","summary":"EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME - Modern Retina","headline":"EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNa0hEYU14cU9mUXE2SkNDTXJ6M2NTUjlRT1k4dnNNOFBxQ3drTDN2S1pjdDNzc1FSeTlFT2hNRmxCTm5hNGJlMlFfNElvckl0SklYMmptMjhqcHk4cl9oZlhwdVJ0czdZb0NKUVFrVE9pUUJGbVM1b2V1RGJJOW9sYkdwdjR3SFhwdlozQmUxaEhRWnVJLXcyT2NGcTZRZ3dNcE5BSV9Eajg0VEE1SjhabmlFdWpDSVJP?oc=5","date":"2025-10-09","type":"pipeline","source":"Ophthalmology Times","summary":"Increasing the knowledge base of GA is key to individualizing patient therapy - Ophthalmology Times","headline":"Increasing the knowledge base of GA is key to individualizing patient therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNTThDRURxeFlCUkIxME9PMWJWQ1IyR0tMQlpJcndpUkZxaEkxcm5RNmtkV3h4Vlo4cWxMZXpiZnhUWGIzMktUakN6dXFVSFFtQnpkUm1oWFBmZmplak4xZ1JweFU0MFpkNGtXaFoySDBPU1NPLU5xdmx0YnJuYlBqMjM2WmREWFN5ZE96SE5EeVZrUElETm50X3JSNWg4c3hrX1JtYVVVd1RLV1gzVXpGaWVR?oc=5","date":"2025-08-09","type":"regulatory","source":"Ophthalmology Times","summary":"ASRS 2025: 48-month results from OAKS, DERBY, and GALE open-label extension - Ophthalmology Times","headline":"ASRS 2025: 48-month results from OAKS, DERBY, and GALE open-label extension","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNOEhQZU5SUDBVMVJTV01Lc3VSbFJvLVR4OVRQVXh2Tkc3cXNEaXd3cTJ4MEVfOEN2SFd3cm51Y0JBZ3NyMUVnSHo5V2tRbFNpZk5xMXMwcEZWTWY2QWJsYmdqSi14SmtVUXdfMk9vUG44a3hZUjE3eHdBNzZWM0JxZV9ROEgwRkJ5ZmR0VVZnTWFMUXVpdnZGTmN0dC1VRkdOX0FjUk44djd5b0JVVkFKWWtQdWNLcXVwTVlCc3pja2JuRzdYX3FQVmxiYkpreXh2UTZ1V2NZZmlReGdWanNXV3RSUzFNbjNNd0lLbFJFdHFRdVJraDk5QUMybEh1WDFBYjhvNk85ekI0STM4SWpYNnBiTWpKM3FkYnU3UllfS29id2NXZEttQmE1WTBEelE?oc=5","date":"2025-02-03","type":"trial","source":"PR Newswire","summary":"Avirmax Biopharma Announces Completion of the First Cohort of Patient Enrollment in Clinical Trial of ABI-110, a Gene Therapy for Wet AMD Including PCV - PR Newswire","headline":"Avirmax Biopharma Announces Completion of the First Cohort of Patient Enrollment in Clinical Trial of ABI-110, a Gene Th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxONDB3bDBKUzduQkVtYUM1b3lQaWgwNTZiaDN5MXAyd2tDVUlsSGlMMzZ6TW9WZUZSWFJhYWNUYXFFUHVKUjRIZGlXWGdVMGNIYktuNEFlZGxRV25tNUVURHhYNXFKNG9ydTBwVXl3cnhtb0cwTF9zTXhhWGlSSEgzemx0NG0?oc=5","date":"2024-02-21","type":"pipeline","source":"Ophthalmology Times","summary":"Treating complex cases of nAMD and DME - Ophthalmology Times","headline":"Treating complex cases of nAMD and DME","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOV18xbVVGRENIc051VmY1U0FHeF9wNGl5dWRqUG1JU0JNWEVQOEswclZqakU3MzJwVU9JM1lkZHhuOHB6ZmdhMGR3RU9PaDJwN2txcHpaa0tFbDF6c1F4T3Y4OGhSXzdfakRueFdqbWF1dUthQnJ4allPaE11UExpUVlVT24zVjVUTWd2eVNoSC16T19kdFk0emstb0NwUXFELWMwRGI1bnl5RHM3MGZFOFZac1NGQUo3NG55bUpnZnJtQmpZdGp4RXFkRUNmelRqTWRrZEQyQXdJR2NDRHlWVUFCN1pIaTdmcTlkdXowM2xzVHg1LVZXV2tsclJuSzhEcTVQZVZyeEJnbFpQR3JZTVFkcXRmVE1HZkZTXzVCbUFmeERVY2haX0lKdw?oc=5","date":"2024-01-03","type":"deal","source":"PR Newswire","summary":"Ascend Vision Partners Joins Forces with Bay Area Retina Consultants to bring much needed Uveitis and Retina services to the Greater Tampa Bay area - PR Newswire","headline":"Ascend Vision Partners Joins Forces with Bay Area Retina Consultants to bring much needed Uveitis and Retina services to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBvd3VWaTdlNURibHREVDVYQ1d4M285dFVOSnItdE9vdVNWT2t5Yzk1VUMxN3l2REpwS0NCYnV2Rzg5V2Nmc00zb0xUZ2MxRjJTYTRlbUZR?oc=5","date":"2023-08-08","type":"pipeline","source":"Medscape","summary":"Long-Term Outcomes of Pegcetacoplan for GA Show Promise - Medscape","headline":"Long-Term Outcomes of Pegcetacoplan for GA Show Promise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPbERQVFZET0lxckhWZlRkZm80elg2XzR3eTdRdVcxWnJsRWdEeFE3cTJIU3VKdm9vNGxUeWR6YVB6Y3dpN3hhaHhKQ0tjTFBtT0s3Mktqbm5Pc3ZzWnJHeVFhdnFRM2hNbW9rRzlRTWdjNFdab2gxSjFpTzNiNWdGZGJOMXdaemlZ?oc=5","date":"2023-07-31","type":"pipeline","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Healthcare Acquisitions – June 2023 - Private Equity Stakeholder Project PESP","headline":"Private Equity Healthcare Acquisitions – June 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSFh1dEVqMUFVVjJsVEY3dDVSZ1dWSmVEODNjUDhCSTJyTFB3VWl2clhQR3YtbGFTaEV0cVdmNkJGR3pkWWFuVzFSQURjdE02azN1Rkt5SUpLa2lBcWdBSzVwY3F0cGZtOGFOeXBHanVSNkxpT0RRUENHY3dQc2pjZlRCdlVfc1V6UDlBYmpfODJseWV4OElNYXF4eXhSR2xremtXZTJzQlBqNXc4U2N1WGtWalBKa1Fv?oc=5","date":"2020-11-01","type":"trial","source":"Ophthalmology Times","summary":"Study results link frequent anti-VEGF injections, risk of cognitive impairment - Ophthalmology Times","headline":"Study results link frequent anti-VEGF injections, risk of cognitive impairment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQM3p1RGFTNVVCa1oyZTBDb2pYQ3pWRzRKSTRhVTRWdmlFZTZ2TEhZSlJTUVM2OEstR0lZeGdmOEdQcDRWel95NUFnbF9ZLVVjTFFEYlZMZE9XLUNPa3hHaEdPYXMyMjJhaEllOVlMWkpYeFZMbHBtZ21MSk1hTEhJYjNwNUZCaVdhX0pKSVhSc0ZMbldLUUgwODlaTkxjQkx5bmVYZ241T1hVMUh5Z05ENE1kTTI?oc=5","date":"2018-02-22","type":"pipeline","source":"Bloomberg.com","summary":"Regeneron's Eylea Has Mysterious Rise in Side Effect Reports - Bloomberg.com","headline":"Regeneron's Eylea Has Mysterious Rise in Side Effect Reports","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}